Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease

Sawada, Koji

doi:10.1016/j.transci.2017.08.016

Cited by 1 publication

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leukocytes have an innate propensity to adhere to foreign bodies. The discovery that they can attach strongly to ultrafine polyester fibers laid the basis of this method’s adoption for treating patients with activated leukocyte-associated diseases[ 56 ].…”

Section: Leukocytapheresismentioning

confidence: 99%

“…The system for leukocytapheresis was developed by Asahi Kasei Medical in Japan and was first comprehensively described by Sawada et al [ 56 ]. It also functions as a direct blood perfusion device.…”

Section: Leukocytapheresismentioning

confidence: 99%

“…Cellsorba results in an extensive removal of white blood cell (WBC), and this reduction in WBC has been beneficial to IBD patients[ 59 ]. Sawda et al [ 56 ] also reported LCAP to be effective for IBD patients. In the initial days, the IBD Research Committee in Japan conducted a double-blind trial from 1998 to 2000, which showed statistically significant effectiveness in the LCAP group in comparison with a sham apheresis group[ 56 ].…”

Section: Leukocytapheresismentioning

confidence: 99%

“…Sawda et al [ 56 ] also reported LCAP to be effective for IBD patients. In the initial days, the IBD Research Committee in Japan conducted a double-blind trial from 1998 to 2000, which showed statistically significant effectiveness in the LCAP group in comparison with a sham apheresis group[ 56 ]. Several mechanisms have been proposed by which LCAP assuages IBD.…”

Section: Leukocytapheresismentioning

confidence: 99%

See 3 more Smart Citations

Apheresis: A cell-based therapeutic tool for the inflammatory bowel disease

Yasmin¹,

Najeeb²,

Naeem³

et al. 2022

WJCC

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD) is a hallmark of leukocyte infiltration, followed by the release of cytokines and interleukins. Disease progression to Ulcerative Colitis (UC) or Crohn’s Disease (CD) remained largely incurable. The genetic and environmental factors disrupt enteral bacteria in the gut, which hampers the intestinal repairing capability of damaged mucosa. Commonly practiced pharmacological therapies include 5-aminosalicylic acid with corticosteroids and tumor necrosis factor (TNF)-α. New interventions such as CDP571 and TNF-blocking RDP58 report the loss of patient response. This review discusses the non-pharmacologic selective granulocyte–monocyte-apheresis (GMA) and leukocytapheresis (LCAP) that have been proposed as treatment modalities that reduce mortality. GMA, an extracorporeal vein-to-vein technique, presents a strong safety profile case for its use as a viable therapeutic option compared to GMA's conventional medication safety profile. GMA reported minimal to no side effects in the pediatric population and pregnant women. Numerous studies report the efficacious nature of GMA in UC patients, whereas data on CD patients is insufficient. Its benefits outweigh the risks and are emerging as a favored non-pharmacological treatment option. On the contrary, LCAP uses a general extracorporeal treatment that entraps leukocytes and suppresses cytokine release. It has been deemed more efficacious than conventional drug treatments, the former causing better disease remission, and maintenance. Patients with UC/CD secondary to complications have responded well to the treatment. Side effects of the procedure have remained mild to moderate, and there is little evidence of any severe adverse event occurring in most age groups. LCAP decreases the dependence on steroids and immunosuppressive therapies for IBD. The review will discuss the role of GMA and LCAP.

show abstract

Section: Leukocytapheresismentioning

confidence: 99%

Section: Leukocytapheresismentioning

confidence: 99%